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Herein, we present the case of a patient with recurrent hepatocellular carcinoma (HCC) who had paracaval lymph
node (LN) metastases with an inferior vena cava (IVC) tumor thrombus after a hepatectomy. A 65-year-old man with
chronic hepatitis B virus infection received an extended anterior segmentectomy because of two hepatic tumors,
located in segments 7 and 8. Histological examination of both resected specimens showed mostly moderately
differentiated HCC with some poorly differentiated areas, and liver cirrhosis (A2/F4). Because the patient had an
elevated α-fetoprotein serum level, abdominal computed tomography (CT) was performed. Abdominal CT revealed
a 9-mm-diameter recurrent tumor in hepatic segment 3 and paracaval LN metastases with an IVC tumor thrombus
at 8 months after the first operation. The patient received transcatheter arterial chemoembolization as treatment for
the intrahepatic recurrence, following resection of the paracaval LN metastases and removal of the IVC tumor
thrombus. In this case, the paracaval LN metastases had directly infiltrated the IVC via the lumbar veins, resulting in
an IVC tumor thrombus, which usually develops from an intrahepatic tumor via the hepatic vein. The development
of an IVC tumor thrombus with HCC recurrence, as in this case, is very rare, and based on a PubMed search, we
believe this report may be the first to describe this condition.
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Hepatocellular carcinoma (HCC) is a highly malignant
form of cancer, which recurs frequently after hepatec-
tomy [1]. The most common recurrent sites are the re-
sidual liver and lung; however, occurrence of lymph
node (LN) metastases after hepatectomy is unusual [2].
Some studies have reported that metastatic LNs from
HCC tend not to spread to the surrounding tissue [3].
Furthermore, in only 0.53% of patients with HCC did
the inferior vena cava (IVC) have tumor invasion [4] that
directly progressed from intrahepatic HCC. Therefore,
local resection of HCC is a curative treatment to* Correspondence: ishiyama@hiroshima-u.ac.jp
1Gastroenterological and Transplant Surgery, Applied Life Science, Institute of
Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku,
Hiroshima 734-8551, Japan
Full list of author information is available at the end of the article
© 2013 Imada et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orimprove patient survival. In our case, metastases from
the LNs on the paracaval site, which is an uncommon
site for HCC metastases, directly infiltrated into the IVC
and developed into an IVC tumor thrombus. Although
some investigators have reported that metastatic LNs in-
filtrated the portal venous (PV) wall and developed into
PV tumor thrombi in patients with HCC [3], no reports
have described IVC tumor thrombi from LN metastases
in patients with recurrent HCC. In this report, we de-
scribe a rare progressive pattern of a recurrent HCC
with LN metastases, which showed an infiltrative growth
pattern.
Case presentation
A 65-year-old man with hepatitis B virus (HBV)-related
cirrhosis was admitted to our institution for the treat-
ment of recurrent intrahepatic HCC and paracaval LNtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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thrombus. Eight months before this visit, he had under-
gone a curative operation for HCC at our institution.
This operation involved an extended anterior segmen-
tectomy, including resection of hepatic segment 7, for
the treatment of two hepatic tumors, and the histo-
logical findings of both resected specimens showed
mostly moderately differentiated HCC, with some poorly
differentiated areas, and liver cirrhosis (LC; A2/F4;
Figure 1). During physical examination, there was no ten-
derness in the abdomen, and no mass was palpable at the
time of the administration. The patient’s blood biochem-
ical values showed elevated levels of both serum α-
fetoprotein (AFP; 266 ng/ml; normal, <6.5 ng/ml) and
protein induced by vitamin K absence or antagonist II
(PIVKA-II; 46 mAU/ml; normal, <40 mAU/ml) (Figure 2).
Computed tomography (CT) revealed both enlarged LNs,
measuring 3 cm in diameter, located behind the IVC and
development of an IVC tumor thrombus apart from liver
(Figure 3). Also, preoperative images showed the continu-
ity of the intravascular lumen and the formation of
thrombus consecutively from enlarged LNs through lum-
bar vein. Additionally, CT angiography revealed a 9-mm-
diameter intrahepatic tumor in segment 3; this tumor had
high attenuation on CT during arteriography (CTA) and
low attenuation on CT during arterioportography (CTAP;Figure 1 The primary hepatocellular carcinoma. (A) Dynamic compute
segment 7 and a 20-mm-diameter hypovascular mass in segment 8. (B, C) Gr
examination of the two specimens revealed moderately differentiated HCC. A
there was evidence of tumor invasion into the portal vein (H&E, ×20).Figure 4). Positron-emission tomography (PET) with 18 F-
fluorodeoxyglucose (18 F-FDG) revealed no other areas of
increased uptake, except for an intense area of increased
uptake (SUVmax, 4.0) in the region that corresponded to
the enlarged LNs, as previously seen with CT imaging. On
the basis of these findings, we preoperatively diagnosed
this condition as recurrence of intrahepatic carcinoma and
paracaval LN metastases, with IVC invasion and thrombus
formation. For treating the intrahepatic recurrence, the
patient received transcatheter arterial chemoembolization
(TACE) at the time of the CT angiography. Finally, as
there was no metastasis in any other organs and the HCC
was well controlled, we decided to perform surgical treat-
ment for the LN metastases as a curative treatment.
During the surgical procedure, we made an incision on
the anterior aspect of the IVC and performed a thromb-
ectomy for the IVC tumor thrombus, after clamping
both renal veins and the IVC segment, because the cra-
nial side of the IVC tumor thrombus extended under
the bifurcation of the renal vein. Subsequently, we
performed thrombectomy for the tumor from the lumbar
vein, followed by dissection of the lumbar vein (Figure 5).
The tumor growth was spreading from the lumbar vein,
which branched from the IVC. Additionally, the intra-
operative finding of this case revealed that the border be-
tween the IVC thrombus and the wall of the blood vesseld tomography revealed a 20-mm-diameter hypervascular mass in
oss appearance of the two resected hepatic tumors. (D, E) Microscopic
few of the HCC cells from segment 7 were poorly differentiated, and
Figure 2 Clinical course of the tumor markers.
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we performed a lymphadenectomy after closing the IVC
with a continuous suture. LNs located in a mass behind
the IVC adhered to the peripheral tissue, but we could
complete the surgical procedure with no macroscopic re-
sidual tumor. Pathological examination of the resectedFigure 3 The paracaval lymph node metastases with an inferior vena
enlarged lymph nodes (diameter, 3 cm; arrow), which were located behind
through the lumbar vein (arrowhead).LNs and IVC thrombus revealed giant atypical and pleo-
morphic HCC cells and not vascularized tissue, consistent
with a diagnosis of HCC (Figure 6A, B). In addition, the
HCC cells located in the lymphatic vessel invaded the
drainage vein of resected LNs (Figure 6C, D). Finally, we
diagnosed that LN metastases but not IVC wall metastasescava tumor torombus. (A, B) Computed tomography revealed both
the IVC, and (C, D) IVC tumor thrombus, which directly infiltrated
Figure 4 Computed tomography angiography revealed a 9-mm-diameter intrahepatic recurrence in segment 3.
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into an IVC tumor thrombus.
Hematogenous metastasis from HCC is a well-known
pathway of tumor infiltration and growth, and the most
frequent extrahepatic metastatic sites are the lung,
followed by the adrenal gland and the skeleton [5]. How-
ever, the incidence of an extrahepatic metastasis in HCC
is extremely low [6]. Although autopsy studies have
clarified that the frequency of LN metastases from HCC
are 23.5–43.9%, the detection of LN metastases during
any type of treatment is uncommon and accounts for
only 1.0% of hepatectomy cases [2]. The hepatic lymphatic
system has been well elucidated [7]. In most of the lymphccranialcaudal
A
C
Figure 5 The intraoperative findings and resected specimens. A, B: In
the IVC (arrow) after complete exposure and taping of both the renal veinsnodes, lymph flows toward the hepatic hilum and runs
into the intra-abdominal lymphatic system through the
hepatoduodenal ligament. Therefore, almost all metastatic
LNs from HCC are located in the hepatoduodenal liga-
ment and on the posterior surface of the pancreas head
[8]. However, the progression of liver cirrhosis leads to
lymphatic obstruction and the formation of collateral
routes for lymphatic drainage [2]. This phenomenon may
produce skip metastases, which means no LN metastases
may occur in the proximal hepatoduodenal ligament but
rather at distant sites [9]. In our case, the metastatic LNs
were located behind the IVC, and there were no LN me-
tastases in the corresponding proximal hepatoduodenalcranialaudal
B
cision of the anterior part of the IVC (diamond) and thrombectomy of
(arrowhead) and IVC. C: Gross appearance of the resected LNs.
Figure 6 The pathological examination of the resected LNs and IVC thrombus. A, B: The pathological findings from the resected LNs
revealed giant atypical and pleomorphic HCC cells (H&E; A, ×1.25; B, ×40). C, D: the HCC cells infiltrated into the drainage vein of the lymph
nodes (H&E; C, ×4; D, ×10).
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surgical specimen appeared as LC, and the formation of
collateral routes for lymphatic drainage might have led to
skip metastases.
Ueda et al. suggested that the main drainage routes of
HCC lesions are the portal venules; therefore, HCC may
have a tendency to infiltrate the portal vein and may eas-
ily create a PV tumor thrombus [10]. Morimoto et al. [3]
reported a case of HCC with a PV tumor thrombus from
posterior pancreaticoduodenal LN metastases. In gen-
eral, the main drainage of metastatic LN lesions as well
as primary HCC may be via the portal venules; therefore,
if there are any metastases to LNs, a PV tumor throm-
bus may also be present. However, in our case, there was
a consecutive tumor thrombus from the lumbar vein to
the IVC. We assumed that the development of a tumor
thrombus from the lumbar vein to the IVC was due to
the presence of both lymphogenous and hematogenous
metastases at the local site. This phenomenon greatly
differs from the general findings, showing that paracaval
LN metastases from solid tumors are generally hema-
togenous; however, this patient had bone and lung me-
tastases after the second operation via hematogenous
metastasis from the metastatic LNs. In previous studies
that have reported resection of metastatic LNs from
HCC, the growth of the metastatic focus was almost
noninfiltrative, with no involvement of blood vessels
[11]. In contrast, other investigators have reported thatthe pathological characteristics of metastatic LNs com-
prised those of poorly differentiated HCC and that the
growth patterns of metastatic LNs were infiltrative in pa-
tients with PV tumor thrombus that developed from
metastatic LNs. Corresponding with the findings of the
latter report, a microscopic examination of the resected
LN metastases in our case showed poorly differentiated
HCC, with proliferation in a trabecular or solid pattern.
Lee et al. [12] investigated the clinicopathological char-
acteristics of HCC with LN metastases, and they con-
cluded that having both an infiltrating type and a larger
(>5 cm) tumor with microvascular invasion, as well as a
high-grade histology were associated with higher inci-
dences of LN metastases. Although the size of the HCC
tumor during the first hepatectomy was less than 5 cm
in the present case, histological examination showed that
the HCC cells were giant atypical cells, including pleo-
morphic cells, and had spread to the surrounding nor-
mal liver tissue with no well-defined border and had
invaded the portal vein. Our patient had chronic HBV
infection, but Lee et al. [12] concluded that neither HBV
infection nor hepatitis C virus infection was related to
the development of LN metastases.
Livraghi et al. reported a cohort study of radiofrequency
ablation (RFA) and demonstrated that complete ablation
of lesions smaller than 2 cm is possible in more than 90%
of cases, with a local recurrence rate of less than 1% [13].
Also, Bujold et al. conducted prospective trials of
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and reported that SBRT could lead to sustained local con-
trol, associated with survival rates higher than historical
controls, with a low risk of serious toxicity [14], although
HCC with no metastasis, which is less than 5 cm in diam-
eter, is candidate for SBRT in our country. It seemed that
our patient was a candidate for RFA but not for SBRT
based on the tumor size and location, but we performed
TACE concurrently at the time of CT angiography except
for RFA because of the start of additional prompt treat-
ment for LN recurrence by controlling the intrahepatic le-
sion. Also, we selected aggressive oncological treatment as
a part of multidisciplinary treatments for recurrence in-
stead of conservative treatment. Currently, there is no
consensus regarding treatment strategies for LN metasta-
ses in HCC patients [15]. Zeng et al. and Toya et al. retro-
spectively evaluated the role of radiotherapy (RT) for HCC
patients with LN metastases [16,17]. They showed that the
median survival time (MST) was 9.4 months for the RT
group and 3.3 months for the non-RT group (p < 0.001),
and they concluded that LN metastasis from HCC was
sensitive to RT. Also, Hou et al. evaluated the influence of
PV vs. IVC tumor thrombosis sites on the effectiveness of
RT in advanced HCC with macrovascular invasion. They
concluded that HCC patients with IVC thrombus treated
with RT had a better response rate and longer survival
than those with PV thrombus [18]. In contrast, Kobayashi
et al. compared the treatment results of surgery and RT
for LN metastasis from HCC. They showed that the MST
of patients with single and multiple LN metastases after
surgery was 52 and 14 month, respectively (p < 0.01) and
concluded that selective lymphadenectomy of LN metasta-
sis was a safe and efficacious procedure [11], although a
previous report on regional lymphadenectomy demon-
strated a high rate of liver failure [19]. After examining RT
for treatment of LN metastasis, we selected a surgical
treatment because of the high risk of pulmonary embolism
due to the large size of IVC tumor thrombus with rela-
tively rapid growth without metastasis in any other organs
and the composition of a mass of LNs. Concerning
chemotherapy, although Llovet et al. reported that
sorafenib prolonged median survival time and the time to
progression by nearly 3 months in patients with advanced
HCC in 2008, no standard systemic chemotherapy in pa-
tients with advanced HCC had been established yet [20].
As Bruix et al. discussed, sorafenib is now considered the
first-line treatment in patients with HCC who can no lon-
ger be treated with potentially more effective therapies
across the world [21]. In our case, he received S-1 plus cis-
platin as an adjuvant therapy after the second surgical pro-
cedures, and he additionally received sorafenib after the
spreading of HCC metastasis to the bone and lung. In the
same way, concerning the role of neoadjuvant chemother-
apy in HCC patients, Samuel et al. concluded that therewas no clear evidence to show that neoadjuvant therapy
increases survival from HCC [22]. However, Williet et al.
reported the first case of a patient with HCC with LN me-
tastases treated by sorafenib combined with gemcitabine
plus oxaliplatin, with a partial response, which allowed
curative surgery [23], and it is still a matter of debate.
Conclusions
In conclusion, our patient had an uncommon pattern of
progression and growth of HCC, with LN metastases that
comprised HCC and infiltrated the IVC and produced an
IVC tumor thrombus. Surgeons should consider the possi-
bility of LN skip metastases and infiltrative growth pat-
terns with tumor thrombi after hepatectomies.
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